Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) will report financial results for the quarter ended March 31, 2026 before market open on May 12, 2026 and will host a conference call at 8:00 AM ET the same day to discuss results.
Registration is required for analysts who wish to ask questions; an audio-only webcast will be available via the company investor website. Earnings release and slide presentation will be posted in Investor Relations.
Positive
- None.
Negative
- None.
News Market Reaction – HBIO
On the day this news was published, HBIO declined 5.56%, reflecting a notable negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $28.87M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HBIO shows a modest -0.44% move with low relative volume, while sector peers are mixed (e.g., NXGL -5.89%, RVP +1.58%, MHUA -27.18%). Momentum scanner only flags NEPH moving down, reinforcing a stock-specific backdrop.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings call scheduling | Neutral | -0.5% | Announced Q4 2025 results timing and 8:00 AM ET conference call. |
| Oct 30 | Earnings call scheduling | Neutral | +41.1% | Set Q3 2025 results date and conference call with webcast access. |
| Aug 04 | Earnings call scheduling | Neutral | +10.9% | Announced Q2 2025 earnings release and investor conference call. |
| May 05 | Earnings call scheduling | Neutral | -9.1% | Outlined Q1 2025 results release timing and call logistics. |
| Feb 24 | Earnings call scheduling | Neutral | -6.0% | Scheduled Q4 2024 earnings release and morning conference call. |
Scheduling earnings conference calls with similar tags has produced mixed 24-hour moves, ranging from notable gains to declines, indicating that reactions often depend on expectations around the upcoming results rather than the scheduling notice itself.
Recent HBIO news shows a sequence of quarterly earnings call scheduling under the same conferences,earnings tag. Over 2025–2026, the company repeatedly announced call dates and pre-market releases for quarterly results, with price reactions from -9.06% to +41.1%. This Q1 2026 scheduling mirrors those prior notices, again setting expectations for a pre‑open release and 8:00 AM ET discussion, with webcast access and materials via Investor Relations.
Historical Comparison
In the past year, HBIO issued 5 similar conferences/earnings scheduling releases, with an average absolute move of 7.29%. Today’s Q1 2026 call notice follows that established pattern of pre‑open release and 8:00 AM ET discussion.
The company has consistently announced quarterly earnings calls in advance, maintaining a recurring cadence from Q4 2024 through Q4 2025. This Q1 2026 notice continues that pattern of structured communication to investors around results.
Regulatory & Risk Context
An effective S-3 resale registration dated January 30, 2026 covers up to 9,500,000 shares of common stock for selling securityholders, including shares issuable upon exercise of warrants at $0.50 and conversion of a $7.5 million Term C convertible loan at $1.00 per share. The company itself receives no proceeds from resales, aside from potential warrant exercise proceeds.
Market Pulse Summary
The stock moved -5.6% in the session following this news. A negative reaction despite this being a routine scheduling notice would fit a pattern where even neutral conferences/earnings communications have occasionally coincided with declines. The announcement simply confirms the Q1 2026 release date and call logistics, so any larger downside could reflect broader positioning or expectations into the results. The effective resale registration for 9,500,000 shares may also stay in focus for some investors.
AI-generated analysis. Not financial advice.
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
